Sales & Marketing News | pharmaphorum

News

Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.

News

PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation pricing in Medicare Part B in a US district court.

News

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.

News

MSD has been rocked by a court judgment ordering it to stop making and selling subcutaneous Keytruda in eight European markets.

News

Online pharmacies operating in the UK breached Advertising Standards Authority rules by promoting oral weight drugs to the public.

News

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.